Major new survey on active surveillance and prostate cancer

In February, a group of researchers initiated a major new survey of patient knowledge about active surveillance as an initial management option for men with lower risk forms of prostate cancer. … READ MORE …

Xofigo 2.0

Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …

Another new urine test for risk of prostate cancer

As we have mentioned previously, data on the use of a variety of methods of urine testing in assessment of risk for clinically significant prostate cancer (and therefore the need for a follow-up biopsy) continues to evolve. … READ MORE …

Lu-177-PSMA-617 vs Jevtana (cabazitaxel): which should I do next?

We saw recently (see this link) that of chemotherapeutic and hormonal medicines for treatment of metastatic castration-resistant prostate cancer (mCRPC), Jevtana (cabazitaxel) is the preferred third-line treatment after Taxotere (docetaxel) and Zytiga (abiraterone acetate) or Xtandi (enzalutamide). … READ MORE …

AS and management of Grade Group 2 prostate cancer

The abstract of a presentation to be given by Egan et al. — from the National Institutes of Health (NIH) at Bethesda, MD — at the upcoming, virtual Genitourinary Cancers Symposium has indicated that active surveillance (AS) seems to be a very reasonable option for first-line management for compliant patients initially diagnosed with Grade Group 2 prostate cancer. … READ MORE …

Risk for and detection of clinically significant prostate cancer in previously unbiopsied patients

The “best” way to identify clinically significant, localized prostate cancer continues to evolve. But there is still no consensus about what that “best” way might be to do this, let alone any consensus about the detection of “clinically insignificant”, localized prostate cancer. … READ MORE …

ADT and risk for COVID-19 infection?

Early in 2020, in the initial stages of the COVID-19 pandemic, there was a suggestion (based on data from a small Italian study) that men who were using androgen deprivation therapy (ADT) to manage their prostate cancer might be at lower than average risk for becoming infected with this virus. … READ MORE …

Avoiding radiation damage to salivary glands with Ac-225-PSMA-617 therapy

As we await the results of the VISION trial of Lu-177-PSMA-617, research continues into improving radiopharmaceuticals. … READ MORE …

“Dose painting”: simultaneous integrated boost to the dominant intraprostatic lesion

Two technologies have come together to allow for a new kind of radiation treatment known as simultaneous integrated boost (SIB), or, more informally, “dose painting.” … READ MORE …

SBRT for high-risk prostate cancer patients

As we have seen, stereotactic body radiation therapy (SBRT) is a preferred therapy for low- and intermediate-risk patients (see this link). It is effective, safe, convenient, and relatively inexpensive. However, its use for high-risk patients remains controversial. … READ MORE …

Urine testing for risk of prostate cancer: a current and future perspective

It is becoming very clear that over the next 5 to 10 years we will develop a whole new spectrum of urine-based tests for the assessment of risk for prostate cancer and whether a specific patient will actually need a biopsy and/or other tests to confirm diagnosis. … READ MORE…

Mediterranean diet, active surveillance, and low-risk prostate cancer: the details

As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …

Mediterranean diet, active surveillance, and low-risk prostate cancer

The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …

Whole pelvic salvage radiation may be better than precisely targeted lymph node salvage radiation

Last week, I looked at a retrospective study of metastasis-directed therapy (MDT) at the Mayo Clinic among oligorecurrent patients (see this link). … READ MORE …

FDA approves first, oral LHRH antagonist

Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …